Search Results - "Rustum, Y M"

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models by Cao, S, Durrani, F A, Tóth, K, Rustum, Y M

“…Background: Identification and development of drugs that can effectively modulate the therapeutic efficacy and toxicity of chemotherapy remain an unmet…”
Get full text

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview by Vanhoefer, U, Harstrick, A, Achterrath, W, Cao, S, Seeber, S, Rustum, Y M

“…For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With…”
Get full text

Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer : Role of drug sequence and dose by SHOUSONG CAO, RUSTUM, Y. M

“…The basis for current clinical trials in the treatment of colorectal cancer with the combination of irinotecan (CPT-11) and 5-fluorouracil (FUra) with or…”
Get full text

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors by Rustum, Y M, Harstrick, A, Cao, S, Vanhoefer, U, Yin, M B, Wilke, H, Seeber, S

“…Although fluoropyrimidines, in particular, fluorouracil (5-FU) and fluorodeoxyuridine (FdUrd), are active alone and in combination with other agents in a…”
Get more information

Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis by YIN, M. B, LI, Z. R, TOTH, K, CAO, S, DURRANI, F. A, HAPKE, G, BHATTACHARYA, A, AZRAK, R. G, FRANK, C, RUSTUM, Y. M

“…Until recently, the use of Se-methylselenocysteine (MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including…”
Get full text

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study by Tewes, M., Schleucher, N., Achterrath, W., Wilke, H. J., Frings, S., Seeber, S., Harstrick, A., Rustum, Y. M., Vanhoefer, U.

“…Background: To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in…”
Get full text

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) by Vanhoefer, U., Cao, S., Harstrick, A., Seeber, S., Rustum, Y. M.

“…Background Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP). Recently, MRP-expression has been detected in…”
Get full text

Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer by van Laar, J.A.M., Rustum, Y.M., Ackland, S.P., van Groeningen, C.J., Peters, G.J.

“…Despite more than 30 years of intensive studies on new drugs against advanced colorectal cancer, the fluoropyrimidines remain the drugs of choice for systemic…”
Get full text

MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors by Toth, K, Vaughan, MM, Peress, NS, Slocum, HK, Rustum, YM

“…The expression of human MDR1 P-glycoprotein (Pgp) in the capillary endothelial cells of the central nervous system has been demonstrated. The brain capillary…”
Get full text

Modeling of the time-dependency of in vitro drug cytotoxicity and resistance by LEVASSEUR, L. M, SLOCUM, H. K, RUSTUM, Y. M, GRECO, W. R

“…For potential clinical extrapolation of in vitro findings, it is of interest to relate the measured effect of an anticancer agent to concentration and exposure…”
Get full text

Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer by VANHOEFER, U, HARSTRICK, A, KÖHNE, C.-H, ACHTERRATH, W, RUSTUM, Y. M, SEEBER, S, WILKE, H

“…To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as…”
Get full text

S-phase modulation by irinotecan : pilot studies in advanced solid tumors by RAMNATH, N, KHUSHALANI, N, JAVLE, M. M, BERDZIK, J, CREAVEN, P. J, RUSTUM, Y. M, TOTH, K, LITWIN, A. M, INTENGAN, M. E, SLOCUM, H. K, PENDYALA, L, SMITH, P. F, STEWART, C. C, HOFFMAN, J. L

“…Two studies of irinotecan (CPT-11) followed 24 h later by an antimetabolite were conducted. The objectives of the studies were: (1) to determine whether the…”
Get full text

d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors by U Vanhoefer, S Cao, H Minderman, K Toth, B S Skenderis, 2nd, M L Slovak, Y M Rustum

“…Intracellular glutathione (GSH) has been implicated as a regulatory determinant of multidrug resistance protein (MRP) function. The objective of the present…”
Get full text

5-Ethynyluracil (776C85) : modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma by SHOUSOUNG CAO, RUSTUM, Y. M, SPECTOR, T

“…5-Ethynyluracil (EU; 776C85) is a potent inactivator of dihydropyrimidine dehydrogenase, the enzyme that rapidly degrades 5-fluorouracil (FUra). We have…”
Get full text

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines by VANHOEFER, U, MÜLLER, M. R, HILGER, R. A, LINDTNER, B, KLAASSEN, U, SCHLEUCHER, N, RUSTUM, Y. M, SEEBER, S, HARSTRICK, A

“…Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-I-interactive agent topotecan. The…”
Get full text

Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model by SHOUSONG CAO, BLACK, J. D, TROUTT, A. B, RUSTUM, Y. M

“…Irinotecan (CPT-11) is a chemotherapeutic agent that is active in the treatment of a variety of solid tumor malignancies. Diarrhea represents the most common…”
Get full text

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis by Voigt, W, Matsui, S, Yin, M B, Burhans, W C, Minderman, H, Rustum, Y M

“…SN-38 is the active metabolite of the topoisomerase-I (topo-I) inhibitor Irinotecan (CPT-11). Generally, topo-I inhibitors stabilize the complex between topo-I…”
Get more information

Overexpression of Bax Enhances Antitumor Activity of Chemotherapeutic Agents in Human Head and Neck Squamous Cell Carcinoma by Guo, B, Cao, S, Tóth, K, Azrak, R G, Rustum, Y M

“…Overexpression of the Bax protein in human head and neck squamous cell carcinoma A253 cells was reported to result in an increased sensitivity to various…”
Get full text

P-glycoprotein in human sarcoma: evidence for multidrug resistance by Gerlach, J H, Bell, D R, Karakousis, C, Slocum, H K, Kartner, N, Rustum, Y M, Ling, V, Baker, R M

“…Overexpression of an immunologically conserved, cell-surface glycoprotein (P-glycoprotein) is consistently associated with multidrug resistance in cell lines…”
Get more information

PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein by VANHOEFER, U, SHOUSONG CAO, MINDERMAN, H, TOTH, K, SCHEPER, R. J, SLOVAK, M. L, RUSTUM, Y. M

“…Multidrug resistance (MDR) is considered multifactorial and has been associated with overexpression of the multidrug resistance protein (MRP). However,…”
Get full text